As stated before, Tregsplay a key role in the process of immune-escape. cancer is the sixth most common malignancy in the world, accounting for 550, 000 new cases every year [1] and is a term used to group together a number of tumors arising from distinct subsites including nasal cavity, oral cavity, pharynx and larynx. Its association with tobacco and alcohol continues to be investigated and confirmed in various trials [2, 3]. More recent, a growing number of cases of Tos-PEG3-O-C1-CH3COO SCCHN continues to be linked to the Human being Papilloma Disease (HPV), because this disease is involved in 3065% of all SCCHN and up to 80% of oropharyngeal cancers [47]. Current treatment regimens for SCCHN rely on a mix of surgery, radiotherapy and systemic therapy, depending on the tumor stage [8, 9]. End result for locoregional advanced disease (stage III/IV) remains dismal due to local recurrence and/or distant metastasis. In Europe the family member survival price for head and neck cancer patients is 72% at one year and 42% at five years [8]. This urges the need for more effective remedies with fewer side effects. In this context, focusing on the tumor microenvironment with immunotherapy may present a potential approach to get the control of head and neck cancer. The tumor microenvironment is a unique and complex environment that emerges during the course of tumor progression [10]. It includes fibroblasts, stroma and immune cells, including those mediating adaptive immunity as well as effectors of innate immunity. To lymphocytes, including CD3+CD4+and CD3+CD8+T cells, are the predominant component of the tumor microenvironment in solid tumors [10, 11]. In addition to To cells, macrophages (M1 and M2 macrophages), natural fantastic (NK) cells, and dendritic cells (DCs) also infiltrate tumor cells [1013]. Research has shown that CD4+T helper cells, CD8+cytotoxic To cells, NK cells, M1 macrophages and DCs are protective against tumor growth and that a coordinated and balanced interaction of those subsets is needed to protect the host against a developing tumor [14]. Conversely, CD4+forkhead box P3+(FoxP3+) regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) promote tumor growth [14]. Tregs, which are characterized by the presence of FoxP3, involved in the development and function of those cells, play a key role in the process of immune-escape by producing the immunosuppressive cytokines IL-10 and TGF-, and by consuming IL-2. Consequently, Tregsexpress the bad co-stimulatory checkpoint inhibitors such as CTLA-4 and PD-1, which dampen T-cell activity when bound to their respective ligands [1517]. The process of immune-escape is further regulated by MDSCs which inhibit lymphocyte function FANCE by inducing Tregcells, producing TGF-, depleting or sequestering the amino acids required for T cell function, or nitrating To cell receptors or chemokine receptors on tumor-specific To cells [18, 19]. Figure1is a simplified schema of the conversation between tumor and immune cells. == Fig. 1 . == Simplified schema from the interaction between tumor and immune cells. CD4+(Th1) To cells produce IFN, which in turn mediates the expansion, differentiation, and activation of tumor-specific CD8+T cells. As a result of the complex conversation between the tumor and cytotoxic T cells (TCR-MHC I/ peptide), large levels of granzymes and perforin are released from these cells, resulting in granule exocytosis and tumor cell death via apoptosis. Both FoxP3+Tregcells and MDSCs play a critical role during the selection of high-avidity CD8+T cells, reducing the functionality of CD8+T cells. IFN interferon gamma, MDSCmyeloid-derived suppressor cell, MHC Imajor histocompatibility complex I, TCRT cell receptor Next, a powerful interaction takes place between immune cells and the tumor itself, called immunoediting [10]. The process of immunoediting reflects the dual role of the immune system in promoting web host protection against cancer and facilitating tumor get away from Tos-PEG3-O-C1-CH3COO immune destruction. All those cancer clones that are able to get away the immune system possess a survival advantage. Based on the conversation between tumor and immune cells, there are three phases in the process of immunoediting: (1) elimination where cancerous cells are eliminated following immunosurveillance, (2) equilibrium where transformed cells are held in control but are no longer eliminated and (3) get away where tumor cell modifications result in lack of immune Tos-PEG3-O-C1-CH3COO response and shape Tos-PEG3-O-C1-CH3COO disease progression [10, 11]. In recent years it has.